Evidence map›Paper›PMID 36894982›Full record

ArticleMalaria journal2023

Novel Plasmodium falciparum k13 gene polymorphisms from Kisii County, Kenya during an era of artemisinin-based combination therapy deployment.

Josephat Nyabayo Maniga, Mong'are Samuel, Odda John, Masai Rael, Jacqueline Njeri Muchiri, Pacifica Bwogo, Odoki Martin, Vidya Sankarapandian, Mfitundinda Wilberforce, Ochweri Albert and 4 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. NovelAntimicrobial agents and chemotherapy · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Josephat Nyabayo ManigaDepartment of Medical Microbiology and Immunology, Kampala International University Western Campus, Bushenyi, Uganda. josnyabayo@yahoo.com.
Mong'are SamuelSchool of Health Sciences, Kisii University, Kisii, Kenya.
Odda JohnSchool of Pharmacy, Kampala International University Western Campus, Bushenyi, Uganda.
Masai RaelDepartment of Biological Sciences, Kisii University, Kisii, Kenya.
Jacqueline Njeri MuchiriSchool of Pharmacy, Kampala International University Western Campus, Bushenyi, Uganda.
Pacifica BwogoDepartment of Biological Sciences, Kisii University, Kisii, Kenya.
Odoki MartinDepartment of Medical Microbiology and Immunology, Kampala International University Western Campus, Bushenyi, Uganda.
Vidya SankarapandianDepartment of Medical Microbiology and Immunology, Kampala International University Western Campus, Bushenyi, Uganda.
Mfitundinda WilberforceSchool of Pharmacy, Kampala International University Western Campus, Bushenyi, Uganda.
Ochweri AlbertSchool of Pharmacy, Kampala International University Western Campus, Bushenyi, Uganda.
Sarah Kemuma OnkobaDepartment of Medical Microbiology and Immunology, Kampala International University Western Campus, Bushenyi, Uganda.
Ismail Abiola AdebayoDepartment of Medical Biochemistry, Molecular Biology and Genetics, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Butare, Rwanda.
Rasheed Omotayo AdeyemoDepartment of Medical Microbiology and Parasitology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Butare, Rwanda.
Saheed Adekunle AkinolaDepartment of Medical Microbiology and Parasitology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Butare, Rwanda.
Kampala International University · UGKisii University · KEUniversity of Rwanda · RWKampala University · UG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, chemotherapy stands out as the major malaria intervention strategy, however, anti-malarial resistance may hamper global elimination programs. Artemisinin-based combination therapy (ACT) stands as the drug of choice for the treatment of Plasmodium falciparum malaria. Plasmodium falciparum kelch13 gene mutations are associated with artemisinin resistance. Thus, this study was aimed at evaluating the circulation of P. falciparum k13 gene polymorphisms from Kisii County, Kenya during an era of ACT deployment.

methodsParticipants suspected to have malaria were recruited. Plasmodium falciparum was confirmed using the microscopy method. Malaria-positive patients were treated with artemether-lumefantrine (AL). Blood from participants who tested positive for parasites after day 3 was kept on filter papers. DNA was extracted using chelex-suspension method. A nested polymerase chain reaction (PCR) was conducted and the second-round products were sequenced using the Sanger method. Sequenced products were analysed using DNAsp 5.10.01 software and then blasted on the NCBI for k13 propeller gene sequence identity using the Basic Local Alignment Search Tool (BLAST). To assess the selection pressure in P. falciparum parasite population, Tajima' D statistic and Fu & Li's D test in DnaSP software 5.10.01 was used.

resultsOut of 275 enrolled participants, 231 completed the follow-up schedule. 13 (5.6%) had parasites on day 28 hence characterized for recrudescence. Out of the 13 samples suspected of recrudescence, 5 (38%) samples were positively amplified as P. falciparum, with polymorphisms in the k13-propeller gene detected. Polymorphisms detected in this study includes R539T, N458T, R561H, N431S and A671V, respectively. The sequences have been deposited in NCBI with bio-project number PRJNA885380 and accession numbers SAMN31087434, SAMN31087433, SAMN31087432, SAMN31087431 and SAMN31087430 respectively.

conclusionsWHO validated polymorphisms in the k13-propeller gene previously reported to be associated with ACT resistance were not detected in the P. falciparum isolates from Kisii County, Kenya. However, some previously reported un-validated k13 resistant single nucleotide polymorphisms were reported in this study but with limited occurrences. The study has also reported new SNPs. More studies need to be carried out in the entire country to understand the association of reported mutations if any, with ACT resistance.

Indexed as

AntimalarialsArtemisininsMalaria, FalciparumArtemetherArtemether, Lumefantrine Drug CombinationDrug ResistanceHumansKenyaPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsAntimalarialsArtemetherArtemether, Lumefantrine Drug CombinationArtemisininsProtozoan ProteinsArtemisinin-based combination therapiesKelch13 propeller genePolymorphismResistance

Identifiers

PMID36894982
PMCPMC9996564
OpenAlexW4323663186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.